Embera NeuroTherapeutics

About:

Embera NeuroTherapeutics is a development-stage pharmaceutical company developing treatments for smoking cessation and other addictions.

Website: http://www.emberaneuro.com

Top Investors: National Institutes of Health, Keiretsu Capital, National Institute on Drug Abuse (NIDA), Keiretsu Forum Northwest, BVM Capital

Description:

Embera NeuroTherapeutics is a development stage pharmaceutical company focused on developing treatments for smoking cessation and other addictions, for which there are a limited range of effective drug therapies or have no approved treatments. Embera is developing a novel addiction treatment (EMB-001) that targets specific and complementary brain functions that drive the craving and relapse associated with these disorders, an approach based on breakthrough discoveries of the scientific founder.

Total Funding Amount:

$28.4M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Sudbury, Massachusetts, United States

Founded Date:

2005-01-01

Founders:

Nicholas Edward Goeders

Number of Employees:

11-50

Last Funding Date:

2021-02-12

IPO Status:

Private

Industries:

© 2025 bioDAO.ai